Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy

ConclusionsConsidering the pleiotropic effects of GLP1-a beyond BMI reduction, this treatment modality may serve as a game changer in challenging cases.

http://link.springer.com/10.1007/s00592-023-02109-9

Source: Acta Diabetologica - May 9, 2023 Category: Endocrinology Source Type: research